Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials (胰高血糖素样肽-1受体激动剂的使用与骨折的关系：一项对随机临床试验的meta分析)

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor

(2013) Guillaume Mabilleau et al.   JOURNAL OF ENDOCRINOLOGY

Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice

(2012) Christine Gaudin-Audrain et al.   BONE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

(2012) M. Nauck et al.   DIABETES OBESITY & METABOLISM

GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation

(2012) Lars Wichmann Madsen et al.   ENDOCRINOLOGY

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia

(2011) B. Gallwitz et al.   DIABETES CARE

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials

(2011) M. Monami et al.   DIABETES CARE

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

(2011) R. Pratley et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes

(2011) Ann V. Schwartz   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide

(2011) Laszlo Hegedüs et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients*

(2011) Mathijs C. BUNCK et al.   Journal of Diabetes

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

(2010) A. Garber et al.   DIABETES OBESITY & METABOLISM

Bone loss accompanying voluntary weight loss in obese humans

(2010) Lars Bjørn Jensen et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States

(2009) Bernardo Nuche-Berenguer et al.   CALCIFIED TISSUE INTERNATIONAL

Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states

(2009) Bernardo Nuche-Berenguer et al.   REGULATORY PEPTIDES

Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)

(2008) S. E. Kahn et al.   DIABETES CARE

The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption

(2007) Chizumi Yamada et al.   ENDOCRINOLOGY